Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LoVAS: Low-dose vs High-dose Glucocorticoids with Rituximab in AAV
NCT02198248Phase 4Unknown
- Sponsor
- Chiba University
- Start
- Oct 2014
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prednisolone in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Chiba University. Primary endpoint: Proportion of patients achieving remission at 6 months. Status: unknown.
02
Drugs
prednisolone
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT02198248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198248.